SYN-TECH Chem. & Pharm. Co., Ltd.

TPEX:1777 Stock Report

Market Cap: NT$4.2b

SYN-TECH Chem. & Pharm Valuation

Is 1777 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1777 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1777 (NT$95.1) is trading above our estimate of fair value (NT$90.21)

Significantly Below Fair Value: 1777 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1777?

Other financial metrics that can be useful for relative valuation.

1777 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.1x
Enterprise Value/EBITDA8.4x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 1777's PE Ratio compare to its peers?

The above table shows the PE ratio for 1777 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25x
1752 Nang Kuang Pharmaceutical
39.2xn/aNT$4.3b
8279 Syngen BiotechLtd
15.6xn/aNT$3.7b
1734 Sinphar PharmaceuticalLtd
15.4xn/aNT$5.6b
4120 Orient EuroPharma
29.7xn/aNT$4.3b
1777 SYN-TECH Chem. & Pharm
14xn/aNT$4.2b

Price-To-Earnings vs Peers: 1777 is good value based on its Price-To-Earnings Ratio (14x) compared to the peer average (25x).


Price to Earnings Ratio vs Industry

How does 1777's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a48.0%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a48.0%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 1777 is good value based on its Price-To-Earnings Ratio (14x) compared to the TW Pharmaceuticals industry average (27.2x).


Price to Earnings Ratio vs Fair Ratio

What is 1777's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1777 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1777's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies